FORMULARY DECISION
Pembrolizumab : Keytruda
SMC2257 : As monotherapy or in combination with platinum and 5-fluorouracil (5-FU) chemotherapy, is indicated for the first-line treatment of metastatic or unresectable recurrent head and neck squamou...
Search Results
All Content Formulary Only Other ContentWe have found 54 results when searching "Pembrolizumab"
FORMULARY DECISION
Pembrolizumab : Keytruda
SMC2375 : As monotherapy for the first-line treatment of metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer in adults. SMC restriction: treatment ...
FORMULARY DECISION
Pembrolizumab : Keytruda
SMC2380 : As monotherapy for the treatment of adult and paediatric patients aged 3 years and older with relapsed or refractory classical Hodgkin lymphoma who have failed autologous stem cell transplan...
FORMULARY DECISION
Pembrolizumab : Keytruda
SMC2420 : In combination with platinum and fluoropyrimidine based chemotherapy, for the first-line treatment of patients with locally advanced unresectable or metastatic carcinoma of the oesophagus or...